[6]
Traynor, K. FDA approves licensing of erenumab-aooe to prevent migraine. J. Health Syst., 2018, 75(13), 929-930.
[10]
Dodick, D.W.; Ashina, M.; Brandes, J.L.; Kudrow, D.; Lanteri-Minet, M.; Osipova, V.; Palmer, K.; Picard, H.; Mikol, D.D.; Lenz, R.A. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia, 2018, 38(6), 1026-1037.
[14]
Goadsby, P.J.; Paemeleire, K.; Broessner, G.; Brandes, J.; Klatt, J.; Zhang, F.; Picard, H.; Lenz, R.; Mikol, D.D. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia, 2019, 39(7), 817-826.
[17]
Lassen, L.H.; Haderslev, P.A.; Jacobsen, V.B.; Iversen, H.K.; Sperling, B.; Olesen, J. CGRP may play a causative role in migraine. Cephalalgia, 2002, 22(1), 54-61.
[19]
Hepp, Z.; Dodick, D.W.; Varon, S.F.; Gillard, P.; Hansen, R.N.; Devine, E.B. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia, 2015, 35(6), 478-488.
[22]
de Hoon, J.; Van Hecken, A.; Vandermeulen, C.; Herbots, M.; Kubo, Y.; Lee, E.; Eisele, O.; Vargas, G.; Gabriel, K. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia, 2019, 39(1), 100-110.
[23]
Lipton, R.B.; Tepper, S.J.; Silberstein, S.; Kudrow, D.; Ashina, M.; Reuter, U.; Dodick, D.; Zhang, F.; Rippon, G.A.; Mikol, D.D. Conversion from chronic to episodic migraine with erenumab, a specific inhibitor of the calcitonin gene-related peptide receptor. J. Headache Pain, 2018, 19.
[24]
Lipton, R.; Tepper, S.; Silberstein, S.; Kudrow, D.; Ashina, M.; Reuter, U.; Dodick, D.; Cheng, S.; Rippon, G.; Zhang, F. Conversion from chronic migraine (CM) to episodic migraine (EM) with long-term erenumab treatment. Neurology, 2019, 92(15)(Suppl)
[26]
Diener, H.C.; Ashina, M.; Brandes, J.; Friedman, D.; Reuter, U.; Tepper, S.; Cheng, S.; Leonardi, D.; Lenz, R.; Mikol, D. Efficacy of erenumab for the treatment of patients with chronic migraine in presence of medication overuse. Eur. J. Neurol., 2017, 24, 472.
[27]
Dodick, D.; Tepper, S.; Diener, H.C.; Tassorelli, C.; Lucas, S.; Evers, S.; Zhang, F.; Chou, D.; Tenenbaum, N.; Klatt, J. Efficacy of erenumab in chronic migraine patients with medication overuse and prior preventive treatment failure. Eur. J. Neurol., 2019, 26, 811.
[28]
Tepper, S.; Diener, H.C.; Ashina, M.; Brandes, J.L.; Friedman, D.T.; Reuter, U.; Cheng, S.; Leonardi, D.; Lenz, R.; Mikol, D. Efficacy of erenumab for the treatment of patients with chronic migraine in presence of medication overuse. Schmerz, 2017, 31(2), S66.
[31]
Ohlsson, L.; Haanes, K.A.; Kronvall, E.; Xu, C.; Snellman, J.; Edvinsson, L. Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. Cephalalgia, 2019, 39(14), 1745-1752.
[32]
Tepper, S.J.; Pascual, J.; Reuter, U.; Picard, H.; Hong, F.; Trotman, M.L.; Xue, F.; Mikol, D.; Klatt, J. Analysis of blood pressure following short-term and long-term treatment with erenumab. J. Headache Pain, 2018, 90(15)(Suppl.)
[38]
Ashina, M.; Kudrow, D.; Reuter, U.; Dolezil, D.; Silberstein, S.; Tepper, S.J.; Xue, F.; Picard, H.; Zhang, F.; Wang, A.; Zhou, Y.; Hong, F.; Klatt, J.; Mikol, D.D. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia, 2019, 39(14), 1798-1808.
[39]
Ashina, M.; Goadsby, P. J.; Reuter, U.; Silberstein, S.; Dodick, D.; Rippon, G. A.; Klatt, J.; Xue, F.; Chia, V.; Zhang, F.; Cheng, S.; Mikol, D. D. Long-term safety and tolerability of erenumab: Threeplus year results from a five-year open-label extension study in episodic migraine. Cephalalgia, Cephalalgia, 2019, 39(1455), 1455-1464.